cold chain raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-30 and is reviewed periodically as new material appears.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
=== Pancreatitis === The incorrect activation of proteolytic enzymes leads to edema, inflammation, and possible pancreas necrosis, causing acute pancreatitis. The most prominent cause of acute pancreatitis is gallstones. Permanent damage is possible from chronic pancreatitis due to progressive inflammation and the reoccurrence of acute pancreatitis. Acute pancreatitis is caused by mutations in a trypsinogen inhibitor, while a mutation in CFTR causes chronic pancreatitis. In fact, chronic pancreatitis often causes pancreatic adenocarcinoma.
== Description == Lemna species grow as simple free-floating thalli on or just beneath the water surface. Most are small, not exceeding 5 mm in length, except Lemna trisulca, which is elongated and has a branched structure. Lemna thalli have a single root, which distinguishes this genus from the related genera Wolffia (lacks roots), Spirodela and Landoltia (have multiple roots). The plants grow mainly by vegetative reproduction: two daughter plants bud off from the adult plant. Lemna are flowering plants, and nearly all of them are known to reproduce sexually, flowering and producing seed under appropriate conditions. Certain species of Lemna (such as L. gibba) are long-day plants, while others (such as L. minor) are short-day plants. Owing to their vegetative reproduction strategies, Lemna species can quickly colonize open water bodies, particularly those with minimal surface flow. Removal of Lemna can be done through mechanical removal (e.g., skimming), biological controls (e.g., herbivorous fish), or treatment with aquatic herbicides. The rapid growth habit of Lemna presents applications in bioremediation of polluted waters, in municipal wastewater treatment, and as test organisms for environmental studies. Species of Lemna are also used as an expression system for economical production of complex biopharmaceuticals. Dried Lemna ("duckweed meal") can be used as livestock feed. It contains 25–45% protein (depending on the growth conditions), 4.4% fat, and 8–10% fibre, measured by dry weight.
=== Construction of the bicyclic core === Myers and co-workers have pioneered the application of transannular anionic cyclization reactions in the synthesis of the 5,9-fused bicyclic core of kedarcidin chromophore and neocarzinostatin chromophore. In the first incarnation, hydride delivery to a cyclic tetrayne was guided by aluminum coordination to a proximal alkoxide, thus generating the desired enediyne core in one step via two successive 5-exo-dig–type cyclizations. Later-generation syntheses of the core intercept this cascade cyclization, relying on lithium-halogen exchange on a cyclic vinyl bromide to generate the vinyl anion precursor to the bicyclic product.
=== Neurodegenerative diseases === AEP is activated during brain ischemia or brain acidosis and epilepsia seizure. It digests SET protein, which is an inhibitor of DNase, leading to DNA damage and causing damage of the brain. Increased activity of AEP in brain is also observed in patients with Alzheimer's disease and Parkinson's disease (PD). AEP cleaves tau protein and amyloid precursor protein. In patients with PD, alpha synuclein is cut by AEP into toxic chunks., which are hypothesized to possibly play a role in the initiation or pathogenesis of PD
==== General election ==== On July 25, 2000, Bush surprised some observers when he selected Dick Cheney – a former White House chief of staff, U.S. representative, and secretary of defense – to be his running mate. At the time, Cheney was serving as head of Bush's vice presidential search committee. Soon after at the 2000 Republican National Convention, Bush and Cheney were officially nominated by the Republican Party. Bush continued to campaign across the country and touted his record as Governor of Texas. During his campaign, Bush criticized his Democratic opponent, incumbent vice president Al Gore, over gun control and taxation. When the election returns were tallied on November 7, Bush had won 29 states, including Florida. The closeness of the Florida outcome led to a recount. The initial recount also went to Bush, but the outcome was tied up in lower courts for a month until eventually reaching the U.S. Supreme Court. On December 9, in the controversial Bush v. Gore ruling, the Court reversed a Florida Supreme Court decision that had ordered a third count, and stopped an ordered statewide hand recount based on the argument that the use of different standards among Florida's counties violated the Equal Protection Clause of the Fourteenth Amendment. The machine recount showed that Bush had won the Florida vote by a margin of 537 votes out of six million casts.
Sources: en.wikipedia.org
=== Implementation === On May 10, 1977, Oklahoma became the first U.S. state to approve lethal injection when Governor David Boren signed a bill into law. Episcopal Reverend Bill Wiseman had introduced it into the Oklahoma legislature, where it passed and was quickly sent to the Governor's desk (Title 22, Section 1014(A)). The next day, Texas became the second U.S. state to approve a lethal injection law. Since then, until 2004, 37 of the 38 states using capital punishment introduced lethal injection statutes (the last state, Nebraska, maintained electrocution as its sole method until adopting injection in 2009, after its Supreme Court deemed the electric chair unconstitutional). On May 11, 1977, the day after the new method had become state law, Oklahoma's state medical examiner, Jay Chapman, proposed a new, less painful method of execution known as Chapman's protocol: "An intravenous (IV) saline drip shall be started in the prisoner's arm, into which shall be introduced a lethal injection consisting of an ultrashort-acting barbiturate in combination with a chemical paralytic." The Chapman protocol was approved by anesthesiologist Stanley Deutsch, formerly Head of the Department of Anesthesiology of the University of Oklahoma College of Medicine. On August 29, 1977, Texas adopted the new method of execution, switching from electrocution. On December 7, 1982, Texas became the first U.S. state or territory in the world to use lethal injection to carry out capital punishment, for the execution of Charles Brooks, Jr.
Playing the Cincinnati Reds on July 20, 2003, Bagwell hit two home runs for the 400th of his career off Danny Graves, becoming the 35th player in MLB history to do so. ESPN's "The List" ranked Bagwell as the second-most underrated athlete of the top four North American professional sports leagues in August 2003, and Biggio third.
=== Cancer and Infectious Diseases === A significant area of LMRT's work involves developing nanomaterials as tools for biological studies and as multifunctional agents for cancer therapies. This includes designing nanoparticles and nanoporous materials that can home in on tumors, signal cellular changes, enhance imaging, or deliver therapeutic components. Early work in 2002, with Erkki Ruoslahti, involved developing phage-derived peptide-targeted nanomaterials for in vivo tumor targeting. More recently, Bhatia, in collaboration with Erkki Ruoslahti and Michael Sailor, has explored engineering beneficial probiotics to detect or treat cancer cells. For over a decade, LMRT has pioneered new technologies in activity-based diagnostics. This includes designing nanosensors with biological molecules, such as peptide barcodes, that can signal the presence of diseases like cancer when interacting with aberrantly active enzymes (proteases) in diseased tissue. These specialized nanoparticles allow for detection via simple tests on urine similar to an at-home pregnancy test, breath, or blood samples. This platform has expanded to detect 12 diseases, including 6 cancer types. Nanosensors can be administered via inhalation, intramuscular injection, and even ingested in the form of probiotic bacteria. The LMRT is also exploring breath-based diagnostics for rapid results and has developed diagnostic tools that use DNA barcodes and CRISPR technology, making cancer diagnostics more affordable and accessible for low- and middle-resource settings.
Writer G. Pascal Zachary argues in a Wired essay that legalizing performance-enhancing substances, as well as genetic enhancements once they became available, would satisfy society's need for übermenschen and reverse the decline in public interest in sports. Sports scholar Verner Moller argues that society is hypocritical when it holds athletes to moral standards, but do not conform to those morals themselves. Fox Sports writer Jen Floyd Engel stated in an article, "We live in a pharmacological society. We live in a society of short cuts, of fake this and enhanced that, and somehow we keep trying to sell the line that sports has become this evil empire of cheating. The reality is athletes are merely doing what so many of us do and celebrate and watch every single day of our lives." Sociologist Ellis Cashmore argues that what is considered doping is too arbitrary: transfusing blood cells is not allowed, but other methods of boosting blood cell count, such as hypobaric chambers, are allowed. Other scholars have advanced similar arguments. In 2023, Australian businessman Aron D'Souza announced the Enhanced Games, a sports event permitting doping. British academic Byron Hyde criticized the Games for coercing retired athletes on low salaries into participating with large financial incentives, but observed that many other sports also coerce athletes into harming themselves for fame or money, including the Olympics. He observed that athletes increasingly face an "enhance or retire" dynamic.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.